Abstract
Concern exists about the risk of nephrotoxicity using tenofovir (TDF) in HIV-infected patients. We performed a retrospective case-control study including 122 consecutive TDF-naive patients who started treatment with TDF-containing regimens and 194 patients receiving antiretroviral therapy with other antiretroviral drugs. During a 12-month observation period 5 (4.1%) patients in the TDF group versus 1 (0.5%) in the control group developed grade 1 or higher serum creatinine elevations (p = 0.018). Only 2 (1.6%) patients discontinued TDF treatment as a result of serum creatinine level elevations. In 4 of the 5 patients developing creatinine elevations TDF was combined with lopinavir-ritonavir. The use of TDF in clinical practice during a 12-month period is associated with low risk of mild renal failure. Further studies to assess long-term renal safety of this drug are needed.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / adverse effects
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Antiretroviral Therapy, Highly Active / adverse effects
-
Antiretroviral Therapy, Highly Active / methods
-
Case-Control Studies
-
Creatinine / analysis
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Female
-
HIV Infections / diagnosis
-
HIV Infections / drug therapy*
-
Humans
-
Incidence
-
Kidney / drug effects
-
Kidney Diseases / chemically induced*
-
Kidney Diseases / epidemiology
-
Kidney Function Tests
-
Male
-
Organophosphonates / adverse effects*
-
Organophosphonates / therapeutic use
-
Probability
-
Prognosis
-
Reference Values
-
Retrospective Studies
-
Reverse Transcriptase Inhibitors / adverse effects*
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Risk Assessment
-
Severity of Illness Index
-
Tenofovir
Substances
-
Organophosphonates
-
Reverse Transcriptase Inhibitors
-
Tenofovir
-
Creatinine
-
Adenine